相关实验视频
Updated: Jul 17, 2025
06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
37.6K
在β-thalassemia中加速动脉样硬化
Julian Hurtado1, Hassan Sellak1, Giji Joseph1
1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States.
American journal of physiology. Heart and circulatory physiology
|September 8, 2023
概括
贝塔thalassemia (BT) 加快动脉样硬化,由于从血液溶解增加的自由血. 血素治疗减少了BT小鼠和血液溶解模型中的斑块积累,这表明血.
科学领域:
- 心血管生物学 心血管生物学
- 血液学 血液学 血液学
- 代谢疾病 代谢疾病
背景情况:
- 贝塔thalassemia (BT) 与心动脉内膜中介厚度的增加有关,这是早期动脉样硬化的一个标志.
- BT病理生理学与动脉样硬化疾病进展之间的直接联系尚不清楚.
- 血液介导的氧化应激被假设是由于血液溶解性贫血和增加的自由血液而促进BT中的动脉样硬化.
研究的目的:
- 为了调查β-thalassemia和动脉样硬化疾病之间的直接关系.
- 评估血素 (HPX) 和德烯 (DFP) 在缓解BT相关动脉样硬化的治疗潜力.
主要方法:
- 使用的野生型 (WT) 和BT小鼠被养高脂肪饮食,具有PCSK9功能增益突变.
- 服用腺相关病毒 (AAV) 介导的血素 (HPX) 疗法.
- 评估了以德费里 (DFP) 为媒介的铁化作用的影响.
- 通过大动脉面部和大动脉根病变分析量化动脉硬性斑块负担.
主要成果:
- 与WT对照组相比,BT小鼠表现出明显增加的动脉样硬化斑块积累.
- 在BT小鼠和由基素诱导的血液溶解模型中,HPX疗法减少了斑块面积.
- 在BT小鼠中,DPP治疗降低了动脉样硬化,但在与HPX结合时没有增加益处.
结论:
- 贝塔thalassemia直接加速动脉样硬化,由血管内血液溶解和增加的自由血.
- 在BT和血液溶解模型中,血素治疗有效降低了动脉样硬化斑块负担.
- 在这种情况下,铁化显示出有效性,但不会增强血素治疗的益处.
相关概念视频
01:30Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
01:38Inflammation
53.8K
Overview
53.8K
01:30Peripheral Artery Disease I: Introduction
9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9
01:30Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20